Jeena Sikho Lifecare (JSLL) Q1 25/26 earnings summary

Executive summary

• Revenue from operations was ₹17,428.59 lakh (₹174.29 crore), up 74% YoY and 25% QoQ; standalone PAT was ₹5,131.14 lakh and consolidated PAT was ₹5,127.14 lakh.

• EBITDA margin reached 45%, versus 25% in Q1FY25 and 34% in Q4FY25; the quarter was the first under Ind AS and the first consolidated reporting period after subsidiary incorporation.

Financial highlights

• EBITDA was ₹7,879 lakh, up 220% YoY and 69% QoQ; margin was 45%, up 2,056 bps YoY and 1,160 bps QoQ.

• EBIT was ₹6,914 lakh, up 257% YoY and 82% QoQ; standalone profit before tax was ₹6,855.03 lakh.

• Gross profit was ₹15,593 lakh; gross profit margin was 89%, versus 89% in Q1FY25 and 91% in Q4FY25.

• Standalone total income was ₹17,535.44 lakh and total expenses were ₹10,680.41 lakh; consolidated PBT was ₹6,850.98 lakh.

• Standalone basic and diluted EPS were ₹4.13 and ₹4.12, respectively; consolidated EPS was also ₹4.13 basic and ₹4.12 diluted.

Outlook and guidance

• FY26 priorities include scaling Panchkarma services and Medicines & OTC sales, improving utilization, launching products, and adding centres and beds.

• Plans include enabling cashless insurance, expanding Government Panel/AYUSH coverage and beginning overseas expansion in the UAE.

• 391 beds were added in Q1FY26, with 360 beds in the pipeline; new capacity had yet to contribute materially to quarterly revenue.

• The Pet Yakrit Pleeha Shuddhi Kit launched, with additional products planned for coming quarters.